Five genes are amplified in > 5% of the corresponding TCGA cohorts: E2F3 (cytoband 6p22.3, 15.7% of bladder cancer), TFRC (3q29, 13.0% of head and neck cancers), MFSD3 (8q24.3, 7.9% of head and neck cancers, FKBP4 (12p13.33, 6.8% of ovarian carcinoma) and FBXL20 (17q12, 6.4% of gastric cancer). This evidence concerns the gene E2F3 and ovarian carcinoma.